Effectiveness of mRNA Vaccines on Cancer With and Without Immune Treatments
DOI:
https://doi.org/10.47611/jsrhs.v12i4.5628Keywords:
mRNA, cancer, cancer biology, microbiology, vaccines, mRNA vaccines, ribosomes, proteins, antigens, antibodies, mouse models, mice, mouse, mouses, tumor, tumors, tumour, tumours, RNA, transcription, translationAbstract
Recently, due to the COVID-19 pandemic’s prevalence across the entire world, scientists pioneered the usage of a new medical technology to fight it and grant humans immunity towards the disease: mRNA vaccines. These vaccines were heavily effective as they prevented a majority of the population from getting COVID-19. This caused scientists to research how mRNA vaccine technology could be utilized for other areas of medicine and disease, especially the world of cancer. This review article will delve into the ways scientists are utilizing the powers of mRNA vaccines to provide treatment to patients with pre-existing cancer, and how they engineered the mRNA vaccine to primarily influence the T-cells to better spot cancer cells, with and without the addition of supportive immunological therapies. It was found that the mRNA vaccines of all types reviewed in this paper were effective against the cancerous tumors, and with supportive immune treatments, the vaccines’ effects were further amplified to varying degrees. However, these vaccines may not translate their results for all types of cancer cells and bodies, though. This is why it is recommended that research must be done on more reliable mouse cell models with more trials to further confirm the effectiveness of the vaccine treatments on the cancerous tumor cells once and for all.
Downloads
References or Bibliography
Chen, J., Ye, Z., Huang, C., Qiu, M., Song, D., Li, Y., & Xu, Q. (2022). Lipid nanoparticle-mediated lymph node–targeting delivery of mrna cancer vaccine elicits robust CD8 + T cell response. Proceedings of the National Academy of Sciences, 119(34). https://doi.org/10.1073/pnas.2207841119
Miao, L., Zhang, Y., & Huang, L. (2021). mRNA vaccine for cancer immunotherapy. Molecular Cancer, 20(1). https://doi.org/10.1186/s12943-021-01335-5
Bialkowski, L., van Weijnen, A., Van der Jeught, K., Renmans, D., Daszkiewicz, L., Heirman, C., Stangé, G., Breckpot, K., Aerts, J. L., & Thielemans, K. (2016). Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours. Scientific Reports, 6(1). https://doi.org/10.1038/srep22509
W., Lim, M., Ding, J., Chen, Y., Aduluso, D., Zetter, B. R., Farokhzad, O. C., & Shi, J. (2021). Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice. Biomaterials, 266, 120431. https://doi.org/10.1016/j.biomaterials.2020.120431
Liu, L., Wang, Y., Miao, L., Liu, Q., Musetti, S., Li, J., & Huang, L. (2018). Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer. Molecular Therapy, 26(1), 45–55. https://doi.org/10.1016/j.ymthe.2017.10.020
Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., Lihm, J., Ceglia, N., Guasp, P., Chu, A., Yu, R., Chandra, A. K., Waters, T., Ruan, J., Amisaki, M., Zebboudj, A., Odgerel, Z., Payne, G., Derhovanessian, E., & Müller, F. (2023). Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature, 618(144-150), 1–7. https://doi.org/10.1038/s41586-023-06063-y
Hernandez, S. P. A., Hersby, D. S., Munk, K. K., Tamhane, T., Trubach, D., Tagliamonte, M., Buonaguro, L., Gang, A. O., Hadrup, S. R., & Saini, S. K. (2023). Three doses of BNT162b2 COVID-19 mRNA vaccine establish long-lasting CD8+ T cell immunity in CLL and MDS patients. Frontiers in Immunology, 13. https://doi.org/10.3389/fimmu.2022.1035344
Toll Like Receptor 7 - an overview | ScienceDirect Topics. (n.d.). Www.sciencedirect.com. https://www.sciencedirect.com/topics/medicine-and-dentistry/toll-like-receptor-7
Published
How to Cite
Issue
Section
Copyright (c) 2023 Rishi Chillara; Jothsna Kethar
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
